PTC/SB/08s (06-03.)
Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Korea Nano Technology

Co., L1d. President and Fellows of

Harvard College International Business

Machines Corp.

Under the Paperwork Reduction Act of 1995, no persons are to a collection of information unless it contains a valid OMB control number. Application Number

Filing Date

INFORMATION DIGGLOCKER						1					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)				First N	First Named Inventor Jin-V			Woo CHEON			
				Art Ur	Art Unit						
				Exam	Examiner Name						
				Attorn	Attorney Docket Number			5252YU-3			
	U.S.PATENTS Remove										
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue E	Issue Date Name of Patentee or Applicant of cited Document			Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1										
If you wis	h to a	dd additional U.S. Pater	nt citatio	n inform	ation pl	lease click	the A	dd button.	_	Add	
			U.S.P	ATENT	APPLI	CATION P	UBLI	CATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹		Publication Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear				
	1	20040115124		2004-0	8-17	Woo et al	-				
If you wish to add additional U.S. Published Application citation information please click the Add button. Add											
FOREIGN PATENT DOCUMENTS Remove											
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²			Publication Date	on	Name of Patentee Applicant of cited Document	e or	Pages,Columns,Line where Relevant Passages or Relevar Figures Appear	74
							\neg		-		$\overline{}$

2003-04-17

2003-07-03

2000-02-02

1	EF2	w	leb	1	n

2 WO 03/053851

3

WO 03/031323

00977212

IB

IB

EP

Application Number Fing Date STATEMENT BY APPLICANT (Not for submission under 37 CFR 1 99) Application Number Fing Date Find Date Find

If you wis	h to a	additional Foreign Patent Document citation information please click the Add button Add					
		NON-PATENT LITERATURE DOCUMENTS Remove					
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					
	1	International Search Report dated August 8, 2005, for PCT Application No. PCT/KR2004/003088					
	2	Written Opinion dated August 8, 2005, for PCT Application No. PCT/KR2004003088					
If you wis	h to a	additional non-patent literature document citation information please click the Add button Add					
		EXAMINER SIGNATURE					
Examiner	Signa	re Date Considered					
		al if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a					

See for Codes of USPTO Platent Documents at year, USPTO, ORD or MEPP 0910.4. * Enter office and assess the document, by the to-elect code (WIPO Standard STI), 3.** Explaines petant conversels, the notices for the year of the region of the Engerer mate procedure the senior instruct for platent document. *
Kind of document by the appropriate symbols as indicated on the document under WIPO Standard STI 16 if possible. **Applicant is to place a check mark here for plant for the platent document.

Control or the procedure symbols as and called on the document under WIPO Standard STI 16 if possible. **Applicant is to place a check mark here for plant places are presented in astrocked.

Application Number Filing Date Filing Date Filing Date First Number Investor Jin-Woo CHECN Art Unit Examiner Name Attorney Docket Number I \$2527U-3

CERTIFICATION STATEMENT

Please see 37	CFR 1.97 and	1.98 to make the appropriate selection(s):
---------------	--------------	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eV1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/97(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- .7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Paul S. Cha/	Date (YYYY-MM-DD)	2006-08-29
Name/Print	Paul S. Cha	Registration Number	54022

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S. 2213.1-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2313.1-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2044 and 2046. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the state of the s
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.